Annual Cash & Cash Equivalents
$44.47 M
-$36.91 M-45.35%
31 December 2023
Summary:
Poseida Therapeutics annual cash & cash equivalents is currently $44.47 million, with the most recent change of -$36.91 million (-45.35%) on 31 December 2023. During the last 3 years, it has fallen by -$39.49 million (-47.04%). PSTX annual cash & cash equivalents is now -78.45% below its all-time high of $206.32 million, reached on 31 December 2021.PSTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$49.34 M
+$18.80 M+61.53%
30 September 2024
Summary:
Poseida Therapeutics quarterly cash and cash equivalents is currently $49.34 million, with the most recent change of +$18.80 million (+61.53%) on 30 September 2024. Over the past year, it has increased by +$23.84 million (+93.47%). PSTX quarterly cash and cash equivalents is now -76.09% below its all-time high of $206.32 million, reached on 31 December 2021.PSTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PSTX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -45.4% | +93.5% |
| 3 y3 years | -47.0% | -75.1% |
| 5 y5 years | +46.3% | - |
PSTX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -78.5% | at low | -76.1% | +93.5% |
| 5 y | 5 years | -78.5% | +46.3% | -76.1% | +93.5% |
| alltime | all time | -78.5% | +184.6% | -76.1% | +93.5% |
Poseida Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $49.34 M(+61.5%) |
| June 2024 | - | $30.55 M(-42.7%) |
| Mar 2024 | - | $53.30 M(+19.8%) |
| Dec 2023 | $44.47 M(-45.4%) | $44.47 M(+74.4%) |
| Sept 2023 | - | $25.50 M(-48.9%) |
| June 2023 | - | $49.91 M(+24.3%) |
| Mar 2023 | - | $40.14 M(-50.7%) |
| Dec 2022 | $81.38 M(-60.6%) | $81.38 M(-50.6%) |
| Sept 2022 | - | $164.81 M(+161.8%) |
| June 2022 | - | $62.96 M(-65.7%) |
| Mar 2022 | - | $183.49 M(-11.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2021 | $206.32 M(+145.7%) | $206.32 M(+4.3%) |
| Sept 2021 | - | $197.81 M(-0.9%) |
| June 2021 | - | $199.69 M(+17.6%) |
| Mar 2021 | - | $169.79 M(+102.2%) |
| Dec 2020 | $83.97 M(-4.3%) | $83.97 M(+26.7%) |
| Sept 2020 | - | $66.27 M(-55.0%) |
| June 2020 | - | $147.13 M(+132.5%) |
| Mar 2020 | - | $63.27 M(-27.9%) |
| Dec 2019 | $87.78 M(+188.8%) | $87.78 M |
| Dec 2018 | $30.39 M(+94.5%) | - |
| Dec 2017 | $15.63 M | - |
FAQ
- What is Poseida Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Poseida Therapeutics?
- What is Poseida Therapeutics annual cash & cash equivalents year-on-year change?
- What is Poseida Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Poseida Therapeutics?
- What is Poseida Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Poseida Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of PSTX is $44.47 M
What is the all time high annual cash & cash equivalents for Poseida Therapeutics?
Poseida Therapeutics all-time high annual cash & cash equivalents is $206.32 M
What is Poseida Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, PSTX annual cash & cash equivalents has changed by -$36.91 M (-45.35%)
What is Poseida Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PSTX is $49.34 M
What is the all time high quarterly cash and cash equivalents for Poseida Therapeutics?
Poseida Therapeutics all-time high quarterly cash and cash equivalents is $206.32 M
What is Poseida Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, PSTX quarterly cash and cash equivalents has changed by +$23.84 M (+93.47%)